Table 2. Clinicopathological and treatment characteristics according to NLR status.
| Characteristics | NLRa <2.5 | NLRa ≥2.5 | P-value |
|---|---|---|---|
| No. of females | 39 | 79 | |
| Group age in years | 0.651 | ||
| ≤40 | 12 (30.8) | 20 (25.3) | |
| 41–59 | 19 (48.7) | 37 (46.8) | |
| ≥60 | 8 (20.5) | 22 (27.8) | |
| Menopausal status | 0.949 | ||
| Premenopausal | 15 (38.5) | 28 (35.4) | |
| Postmenopausal | 23 (59.0) | 49 (62.0) | |
| Missing | 1 (2.6) | 2 (2.5) | |
| hCCIb | 0.507 | ||
| Score 6 | 32 (82.1) | 59 (74.7) | |
| Score ≥7 | 7 (17.9) | 20 (25.3) | |
| Clinical tumor size | 0.297 | ||
| T0 | 0 (0.0) | 3 (3.8) | |
| T2 | 6 (15.4) | 7 (8.9) | |
| T3 | 2 (5.1) | 12 (15.2) | |
| T4 | 30 (76.9) | 55 (69.6) | |
| Missing | 1 (2.6) | 2 (2.5) | |
| Clinical lymph node status | 0.906 | ||
| N0 | 5 (12.8) | 9 (11.4) | |
| N1 | 18 (46.2) | 30 (38.0) | |
| N2 | 7 (17.9) | 18 (22.8) | |
| N3 | 8 (20.5) | 19 (24.1) | |
| Missing | 1 (2.6) | 3 (3.8) | |
| Histologic grade | 0.374 | ||
| Grade II | 5 (12.8) | 6 (7.6) | |
| Grade III | 25 (64.1) | 46 (58.2) | |
| Missing | 9 (23.1) | 27 (34.2) | |
| Site of metastases | 0.768 | ||
| 1 organ | 22 (56.4) | 36 (45.6) | |
| 2 organs | 11 (28.2) | 25 (31.6) | |
| 3 organs | 4 (10.3) | 10 (12.7) | |
| 4 organs | 2 (5.1) | 7 (8.9) | |
| 5 organs | 0 (0.0) | 1 (1.3) | |
| Chemotherapy | 28 (71.8) | 49 (62.0) | 0.399 |
aNeutrophil-to-lymphocyte ratio
bhCCI, hypertension-augmented Charlson comorbidity index